Active substance
Mometasone
- SFDA 42
- US FDA 33
- Health Canada 15
- US price lines 13
- NHS prices 6
- WHO EML 1
- Safety 9
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ALERSON 0.1 % Cream | 0.1 % | Cream · Topical | 1 Tube | SAR 10.45 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ALERSON 0.1 % Ointment | 0.1 % | Ointment · Topical | 1 Tube | SAR 10.45 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| AVOCOM | 0.1 % | Ointment · Topical | 1 Tube | SAR 17.10 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| AVOCOM | 0.1 % | Cream · Topical | 1 Tube | SAR 16.95 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| AVOCOM 0.05% AQUEOUS NASAL SPRAY | 0.05 % | Nasal spray, suspension · Nasal use | 1 Nasal Applicator | SAR 41.60 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| AVOCOM 0.1% OINTMENT 50 g | 0.1 % | Ointment · Topical | 1 Tube | SAR 23.90 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| DEFONEX 0.05% NASAL SPRAY | 0.05 % | Nasal spray · Nasal use | 1 Nasal Applicator | SAR 37.45 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| ECZADERM 0.1% W-W CREAM | 0.1 % | Cream · Topical | 1 Tube | SAR 18.00 | Generic · Prescription | BATTERJEE PHARMACETICAL FACTORY | Valid |
| ECZADERM 0.1% W-W OINTMENT | 0.1 % | Ointment · Topical | 1 Tube | SAR 11.60 | Generic · Prescription | BATTERJEE PHARMACETICAL FACTORY | Valid |
| ELICA 0.1% CREAM | 0.1 % | Cream · Topical | 1 Tube | SAR 19.20 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| ELICA 0.1% OINTMENT | 0.1 % | Ointment · Topical | 1 Tube | SAR 18.00 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| ELOCOM 0.1% CREAM | 0.1 % | Cream · Topical | 1 Tube | SAR 19.95 | NCE · Prescription | Organon Pharma UK Limited | Valid |
| ELOCOM 0.1% OINTMENT | 0.1 % | Ointment · Topical | 1 Tube | SAR 19.95 | NCE · Prescription | N.V. Organon | Valid |
| LOCASONE 0.1% cream | 0.1 % | Cream · Topical | 1 Tube | SAR 13.50 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| LOCASONE 0.1% cream | 0.1 % | Cream · Topical | 1 Tube | SAR 9.05 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| LOCASONE 0.1% cream | 0.1 % | Cream · Topical | 1 Tube | SAR 22.50 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| LOCASONE 0.1% cream | 0.1 % | Cream · Topical | 1 Tube | SAR 45.00 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| METAZ 0.1% W-W OINTMENT | 0.1 % | Ointment · Topical | 1 Tube | SAR 9.95 | Generic · Prescription | COOPER PHARMA | Valid |
| METAZ 0.1% W-W OINTMENT | 0.1 % | Ointment · Topical | 1 Tube | SAR 19.95 | Generic · Prescription | COOPER PHARMA | Valid |
| METAZ CREAM 0.1% | 0.1 % | Cream · Topical | 1 Tube | SAR 19.95 | Generic · Prescription | COOPER PHARMA | Valid |
| METAZ LOTION 0.1% | 0.1 % | Lotion · Topical | 1 Bottle | SAR 31.50 | Generic · Prescription | COOPER PHARMA | Valid |
| MOMATE NASAL SPRAY | 0.05 % | Spray · Nasal use | 1 Nasal Applicator | SAR 22.65 | Generic · Prescription | Glenmark Pharmaceuticals Limited | Valid |
| MOMETAMED 0.1% W-W CREAM | 0.1 % | Cream · Topical | 1 Tube | SAR 10.45 | Generic · Prescription | MEDPHARMA PHARMACEUTICAL & CHEMICAL INDUSTRIES | Valid |
| Mometasone Dawaa Health | 0.05 % (W/W) | Nasal spray · Nasal use | 1 Bottle | SAR 37.45 | Generic · Prescription | Al Dawaa Medical Services Co Ltd | Valid |
| NASONEX 0.05% NASAL SPRAY | 0.05 µg | Nasal spray · Nasal use | 1 Nasal Applicator | SAR 47.55 | NCE · Prescription | Organon Belgium | Valid |
17 more — full table
Indications — CHI Daman Drug Formulary
ANAL FISSURE; BEHCET DISEASE; ECZEMA; HUMAN IMMUNODEFICIENCY VIRUS; PSORIASIS; SEBORRHEIC DERMATITIS; VITILIGO
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MOMETASONE FUROATE | 0.1% | ointment · topical | PADAGIS US | Prescription | 18 Mar 2002 |
| MOMETASONE FUROATE | 0.1% | ointment · topical | ENCUBE | Prescription | 14 Nov 2003 |
| MOMETASONE FUROATE | 0.1% | cream · topical | SUN PHARMA CANADA | Prescription | 21 Dec 2004 |
| MOMETASONE FUROATE | 0.1% | ointment · topical | FOUGERA PHARMS | Prescription | 28 Mar 2005 |
| ASMANEX TWISTHALER | 0.22MG/INH; 0.11MG/INH | powder · inhalation | ORGANON LLC | Prescription | 30 Mar 2005 |
| MOMETASONE FUROATE | 0.1% | lotion · topical | PADAGIS ISRAEL | Prescription | 6 Apr 2005 |
| MOMETASONE FUROATE | 0.1% | cream · topical | COSETTE PHARMS NC | Prescription | 22 May 2006 |
| MOMETASONE FUROATE | 0.1% | ointment · topical | COSETTE PHARMS NC | Prescription | 20 Jun 2006 |
| MOMETASONE FUROATE | 0.1% | lotion · topical | ENCUBE | Prescription | 21 Nov 2007 |
| MOMETASONE FUROATE | 0.1% | lotion · topical | FOUGERA PHARMS | Prescription | 29 Nov 2007 |
| ASMANEX HFA | 0.10MG/INH; 0.20MG/INH; 0.05MG/INH | aerosol, metered · inhalation | ORGANON LLC | Prescription | 25 Apr 2014 |
| MOMETASONE FUROATE | 0.05MG/SPRAY | spray, metered · nasal | APOTEX | Prescription | 22 Mar 2016 |
| MOMETASONE FUROATE | 0.05MG/SPRAY | spray, metered · nasal | AMNEAL PHARMS | Prescription | 3 Apr 2017 |
| SINUVA | 1.35MG | implant · implantation | INTERSECT ENT INC | Prescription | 8 Dec 2017 |
| MOMETASONE FUROATE | 0.1% | ointment · topical | TORRENT | Prescription | 13 Jul 2018 |
| NASONEX 24HR ALLERGY | 0.05MG/SPRAY | spray, metered · nasal | PERRIGO PHARMA INTL | Over-the-counter | 17 Mar 2022 |
| MOMETASONE FUROATE | 0.05MG/SPRAY | spray, metered · nasal | AUROBINDO PHARMA | Prescription | 18 Mar 2024 |
| MOMETASONE FUROATE | 0.05MG/SPRAY | spray, metered · nasal | NASPRESS | Prescription | 15 May 2025 |
| ELOCON | 0.1% | ointment · topical | ORGANON | Discontinued | 30 Apr 1987 |
| ELOCON | 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | cream · topical | ORGANON | Discontinued | 6 May 1987 |
| ELOCON | 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | lotion · topical | ORGANON | Discontinued | 30 Mar 1989 |
| NASONEX | 0.05MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | spray, metered · nasal | ORGANON LLC | Discontinued | 1 Oct 1997 |
| MOMETASONE FUROATE | 0.1% | ointment · topical | SUN PHARMA CANADA | Discontinued | 3 Dec 2004 |
| MOMETASONE FUROATE | 0.1% | cream · topical | FOUGERA PHARMS | Discontinued | 8 Apr 2005 |
| MOMETASONE FUROATE | 0.1% | lotion · topical | SUN PHARMA CANADA | Discontinued | 15 Mar 2006 |
8 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-MOMETASONE | 02403587 | 50 MCG / ACT | SPRAY (METERED-DOSE) · NASAL | APOTEX INC |
| ASMANEX TWISTHALER | 02243595 | 200 MCG / ACT | POWDER · INHALATION | ORGANON CANADA INC. |
| ASMANEX TWISTHALER | 02243596 | 400 MCG / ACT | POWDER · INHALATION | ORGANON CANADA INC. |
| ASMANEX TWISTHALER | 02438690 | 100 MCG / ACT | POWDER · INHALATION | ORGANON CANADA INC. |
| ELOCOM | 00851736 | 0.1 % | OINTMENT · TOPICAL | ORGANON CANADA INC. |
| ELOCOM | 00851744 | 0.1 % | CREAM · TOPICAL | ORGANON CANADA INC. |
| ELOCOM | 00871095 | 0.1 % | LOTION · TOPICAL | ORGANON CANADA INC. |
| MOMETASONE | 02519127 | 50 MCG / ACT | SPRAY (METERED-DOSE) · NASAL | SANIS HEALTH INC |
| MOMETASONE | 02551756 | 50 MCG / ACT | SPRAY (METERED-DOSE) · NASAL | SIVEM PHARMACEUTICALS ULC |
| NASONEX | 02238465 | 50 MCG / ACT | SPRAY (METERED-DOSE) · NASAL | ORGANON CANADA INC. |
| SANDOZ MOMETASONE | 02449811 | 50 MCG / ACT | SPRAY (METERED-DOSE) · NASAL | SANDOZ CANADA INCORPORATED |
| TARO-MOMETASONE CREAM | 02367157 | 0.1 % / W/W | CREAM · TOPICAL | TARO PHARMACEUTICALS INC |
| TARO-MOMETASONE LOTION | 02266385 | 0.1 % / W/W | LOTION · TOPICAL | TARO PHARMACEUTICALS INC |
| TEVA-MOMETASONE | 02248130 | 0.1 % | OINTMENT · TOPICAL | TEVA CANADA LIMITED |
| TEVA-MOMETASONE | 02475863 | 50 MCG / ACT | SPRAY (METERED-DOSE) · NASAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ASMANEX TWISTHALER 110 MCG #30 | $88.83058 | per EA | 23 Sep 2026 |
| US NADAC | ASMANEX TWISTHALER 220 MCG #14 | $36.98 | per EA | 22 Apr 2026 |
| US NADAC | ASMANEX TWISTHALER 220 MCG #30 | $96.04106 | per EA | 23 Sep 2026 |
| US NADAC | ASMANEX TWISTHALER 220 MCG #60 | $112.64988 | per EA | 23 Sep 2026 |
| US NADAC | MOMETASONE FUROATE 0.1% CREAM | $0.42021 | per GM | 23 Sep 2026 |
| US NADAC | MOMETASONE FUROATE 0.1% CREAM | $0.28693 | per GM | 23 Sep 2026 |
| US NADAC | MOMETASONE FUROATE 0.1% OINT | $0.29224 | per GM | 23 Sep 2026 |
| US NADAC | MOMETASONE FUROATE 0.1% OINT | $0.20768 | per GM | 23 Sep 2026 |
| US NADAC | MOMETASONE FUROATE 0.1% SOLN | $0.47768 | per ML | 23 Sep 2026 |
| US NADAC | MOMETASONE FUROATE 0.1% SOLN | $0.48751 | per ML | 23 Sep 2026 |
| US NADAC | MOMETASONE FUROATE 50 MCG SPRY | $1.58728 | per GM | 23 Sep 2026 |
| US NADAC | NASONEX 24HR ALLERGY 50 MCG NASAL SPRAY | $1.19339 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Mometasone 0.1% cream | £2.97 | 30 gram | 1 Oct 2026 |
| NHS Drug Tariff | Mometasone 0.1% cream | £9.90 | 100 gram | 1 Oct 2026 |
| NHS Drug Tariff | Mometasone 0.1% ointment | £4.32 | 30 gram | 1 Oct 2026 |
| NHS Drug Tariff | Mometasone 0.1% ointment | £12.44 | 100 gram | 1 Oct 2026 |
| NHS Drug Tariff | Mometasone 0.1% scalp lotion | £4.36 | 30 ml | 1 Oct 2026 |
| NHS Drug Tariff | Mometasone 50micrograms/dose nasal spray | £2.43 | 140 dose | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 25.1. Antiasthmatic and medicines for chronic obstructive pulmonary disease · core
Therapeutic equivalent to budesonide for Asthma
Safety signals and safety-related labeling changes
- US FDA 7 Jul 2026 RYALTRIS — safety-related labeling change
Labeling sections changed: Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 6 Jul 2026 ELOCON — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 6 Jul 2026 ELOCON — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 6 Jul 2026 ELOCON — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 20 Jan 2023 SINUVA — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 28 Jun 2022 NASONEX — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 16 Feb 2021 ASMANEX TWISTHALER — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 12 Aug 2019 ASMANEX HFA — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 12 Aug 2019 DULERA — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Mometasone
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.